English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Estimates of the worldwide incidence and mortality from 27 cancers in 2008 have been prepared for 182 countries by the International Agency for Research on Cancer (Ferlay et al., 2010). Overall, an estimated 12.7 million new cancer cases and 7.6 million cancer deaths occur in 2008, with 56% of new cancer cases and 63% of the cancer deaths occurring in the less developed regions of the world. The most commonly diagnosed cancers worldwide are lung (1.61 million, 12.7% of the total), breast (1.38 million, 10.9%) and colorectal cancers (1.23 million, 9.7%). Cancer is neither rare anywhere in the world, nor mainly confined to highresource countries. Many cancer subjects die from cancer as a result of organ failure due to “metastasis” (Geiger & Peeper, 2009), thus indicating that medical control of tumor metastasis leads to a marked improvement in cancer prognosis. The acquisition of the metastatic phenotype is not simply the result of oncogene mutations, but instead is achieved through an interstitial stepwise selection process (Mueller & Fusenig, 2004). The dissociation and migration of cancer cells, together with a breakdown of basement membranes between the parenchyme and stroma, are a prerequisite for tumor invasion. The next sequential events involved in cancer metastasis include the following: (i) penetration of cancer cells to adjacent vessels (i.e., intravasation); (ii) suppressed anoikis (i.e., suspension-induced apoptosis) of cancer cells in blood flow; and (iii) an extravascular migration and re-growth of metastatic cells in the secondary organ. For an establishment of anti-metastasis therapy, it is important to elucidate the basic mechanism(s) whereby tumor metastasis is achieved through a molecular event(s). Hepatocyte growth factor (HGF) was discovered and cloned as a potent mitogen of rat hepatocytes in a primary culture system (Nakamura et al., 1984, 1989; Nakamura, 1991). Beyond its name, HGF is now recognized as an essential organotrophic regulator in almost all tissues (Nakamura, 1991; Rubin et al., 1993; Zarnegar & Michalopoulos, 1995; Birchmeier & Gherardi, 1998; Nakamura & Mizuno, 2010). Actually, HGF induces mitogenic, motogenic

Endocrine Delivery System of NK4, an HGF-Antagonist and Anti-Angiogenic Regulator, for Inhibitions of Tumor Growth, Invasion and Metastasis